Repository logo
 

Mouse TAPBPR shows functional similarity to human TAPBPR in shaping the MHC-I immunopeptidome.

Accepted version
Peer-reviewed

Change log

Abstract

Human TAPBPR is known to function as a Major Histocompatibility Complex class I (MHC-I) peptide exchange catalyst that shapes the peptide repertoire presented to immune cells. However, investigations characterizing TAPBPR from other species are limited. Here, we characterize mouse TAPBPR, exploring its association partners in mouse cell lines and comparing its function to human TAPBPR. We find that mouse TAPBPR binds MHC-I and calnexin, with a notably sustained interaction with H2-Db compared to H2-Kb. We reveal that mouse TAPBPR restricts the peptide repertoire presented on H2-Db and H2-Kb on MC-38 cells. Intriguingly, mouse TAPBPR presence promotes the selection of peptides with a C-terminal methionine on H2-Kb. We reveal that in the presence of high-affinity peptides, mouse TAPBPR can promote loading of both H2-Db and H2-Kb. Furthermore, mouse TAPBPR efficiently loaded a peptide with a C-terminal methionine onto H2-Kb. Together, our findings suggest that mouse TAPBPR plays an important role in shaping the MHC-I immunopeptidome by functioning as a peptide editor, similar to its human counterpart.

Description

Journal Title

Front Immunol

Conference Name

Journal ISSN

1664-3224
1664-3224

Volume Title

Publisher

Frontiers

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Cancer Research UK (25343)
Wellcome Trust (219479/Z/19/Z)
Wellcome Trust (104647/Z/14/Z)
JBA, AFA, AM, AN, AAT, and LHB were supported by the Wellcome (Grant numbers 104647/Z/14/Z and 219479/Z/19/Z). IH was supported by a CRUK Immunology project award (Grant number A25343). AA was supported by a Wellcome Doctoral Studentship (220012/Z/19/Z). The work of MW, JB and JSW was funded by Deutsche Forschungsgemeinschaft under Germany‘s Excellence Strategy (Grant EXC2180-390900677), German Cancer Consortium (DKTK), Deutsche Forschungsgemeinschaft (DFG Grant WA 5340/6-1), Deutsche Krebshilfe (German Cancer Aid, 70114948), InvestBW (BW1_4064/03), Else Kröner Fresenius Foundation (EKFS 2022_EKSE.79) and Carl Zeiss Stiftung (P2024-02-012), all awarded to JSW